Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.
Patnaik A, Haluska P, Tolcher AW, Erlichman C, Papadopoulos KP, Lensing JL, Beeram M, Molina JR, Rasco DW, Arcos RR, Kelly CS, Wijayawardana SR, Zhang X, Stancato LF, Bell R, Shi P, Kulanthaivel P, Pitou C, Mulle LB, Farrington DL, Chan EM, Goetz MP. Patnaik A, et al. Among authors: papadopoulos kp. Clin Cancer Res. 2016 Mar 1;22(5):1095-102. doi: 10.1158/1078-0432.CCR-15-1718. Epub 2015 Nov 18. Clin Cancer Res. 2016. PMID: 26581242 Clinical Trial.
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
Lin CC, Calvo E, Papadopoulos KP, Patnaik A, Sarantopoulos J, Mita AC, Preston GG, Mita MM, Rodon J, Mays T, Yeh IT, O'Rourke P, Takimoto CH, Dancey JE, Chen H, Tolcher AW. Lin CC, et al. Among authors: papadopoulos kp. Cancer Chemother Pharmacol. 2009 May;63(6):1065-71. doi: 10.1007/s00280-008-0811-x. Epub 2008 Sep 16. Cancer Chemother Pharmacol. 2009. PMID: 18795291 Clinical Trial.
Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors.
Ricart AD, Berlin JD, Papadopoulos KP, Syed S, Drolet DW, Quaratino-Baker C, Horan J, Chick J, Vermeulen W, Tolcher AW, Rowinsky EK, Rothenberg ML. Ricart AD, et al. Among authors: papadopoulos kp. Clin Cancer Res. 2008 Dec 1;14(23):7947-55. doi: 10.1158/1078-0432.CCR-08-0864. Clin Cancer Res. 2008. PMID: 19047127 Clinical Trial.
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.
Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, Murphy B, Roth B, McCaffery I, Gorski KS, Kaiser B, Zhu M, Deng H, Friberg G, Puzanov I. Tolcher AW, et al. J Clin Oncol. 2009 Dec 1;27(34):5800-7. doi: 10.1200/JCO.2009.23.6745. Epub 2009 Sep 28. J Clin Oncol. 2009. PMID: 19786654 Clinical Trial.
Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas.
Mita MM, Spear MA, Yee LK, Mita AC, Heath EI, Papadopoulos KP, Federico KC, Reich SD, Romero O, Malburg L, Pilat M, Lloyd GK, Neuteboom ST, Cropp G, Ashton E, LoRusso PM. Mita MM, et al. Among authors: papadopoulos kp. Clin Cancer Res. 2010 Dec 1;16(23):5892-9. doi: 10.1158/1078-0432.CCR-10-1096. Clin Cancer Res. 2010. PMID: 21138873 Clinical Trial.
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.
Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, Riisnaes R, Pope LL, Heaton SP, Thomas G, Garrett MD, Sullivan DM, de Bono JS, Tolcher AW. Yap TA, et al. J Clin Oncol. 2011 Dec 10;29(35):4688-95. doi: 10.1200/JCO.2011.35.5263. Epub 2011 Oct 24. J Clin Oncol. 2011. PMID: 22025163 Clinical Trial.
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS, Gunn S, Smetzer L, Mays TA, Kaiser B, Wick MJ, Alvarez C, Cavazos A, Mangold GL, Patnaik A. Shimizu T, et al. Among authors: papadopoulos kp. Clin Cancer Res. 2012 Apr 15;18(8):2316-25. doi: 10.1158/1078-0432.CCR-11-2381. Epub 2012 Jan 19. Clin Cancer Res. 2012. PMID: 22261800
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.
Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchook GS, Dasari A, Shapiro GI, Boylan JF, Xu ZX, Wang K, Koehler A, Song J, Middleton SA, Deutsch J, Demario M, Kurzrock R, Wheler JJ. Tolcher AW, et al. Among authors: papadopoulos kp. J Clin Oncol. 2012 Jul 1;30(19):2348-53. doi: 10.1200/JCO.2011.36.8282. Epub 2012 Apr 23. J Clin Oncol. 2012. PMID: 22529266 Free PMC article. Clinical Trial.
139 results